2025年6月18日，中国人民银行行长潘功胜在2025陆家嘴论坛上，同与会人员分享了其关于全球金融治理的若干思考。讲话中，潘功胜强调了新兴技术在 跨境支付领域中加速应用的现状："区块链和分布式账本等新兴技术推动央行数字货币、稳定币蓬勃发展，实现了'支付即结算'，从底层重塑传统支付体 系，大幅缩短跨境支付链条，同时对金融监管也提出了巨大的挑战。智能合约、去中心化金融等技术也将持续推动跨境支付体系的演进和发展。" 随着讲话稿的逐步传播，稳定币、区块链、web3.0等技术再一次被推上了舆论高潮。毫无疑问，随着全球数字化转型浪潮的深入推进，区块链技术正在重 塑各行业的信任机制与数据交互模式。而在中国，区块链产业从探索期迈向深化应用期，数据要素借由区块链技术达成了自身价值释放，相关企业从技术 追随者开始跃升成为标准制定者。 在2025年7月2日发布的"2025年《财富》中国最具影响力的商界女性"未来榜中，来自趣链科技的首席执行官、正高级工程师邱炜伟女士赫然在列。而她领 导的趣链科技作为区块链领域的领军者，凭借"国产、自主、可控"的技术路线，已经实现从基础研发到全栈产品落地的跨越，服务超过300家国家机构及 头部企业，支 ...

[Music] Hello and welcome to the inaugural episode of Hot Girl Vergecast Summer, the flagship podcast where the hot girls of the Verge replace uh our stinky old men for a summer. No, we love you. We love you. You're not stinky and you're not old. But uh anyway, I'm your friend Victoria Song and I'm filling in this week for David Pierce. Now that he's officially on parental leave. I'll be your guest host for the next two weeks and then I will be handing it off to another one of my beautiful colleagues. It's ...

新能源及有色金属日报 | 2025-07-08 政策及资金扰动持续，多晶硅盘面继续反弹 工业硅： 市场分析 2025-07-07，工业硅期货价格偏弱震荡，主力合约2509开于7980元/吨，最后收于8045元/吨，较前一日结算变化（55） 元/吨，变化（0.69）%。截止收盘，2509主力合约持仓384707手，2025-07-08仓单总数为51349手，较前一日变化 -352手。 供应端：工业硅现货价格持稳。据SMM数据，昨日华东通氧553#硅在8700-8800（0）元/吨；421#硅在8900-9200 （0）元/吨，新疆通氧553价格8000-8200（0）元/吨，99硅价格在8000-8100（0）元/吨。昆明、四川地区部分硅价 仍下降。黄埔港、天津、西北、上海、新疆地区硅价暂稳。 97硅价格同样暂稳。 消费端：据SMM统计，有机硅DMC报价10300-10600（0）元/吨。据SMM统计，6月国内有机硅DMC产量环比5月 增加13.75％，同比减少1.60％。6月国内多数有机硅单体企业开工负荷有所提高。7月虽国内仍有部分单体企业开 工负荷有所下降，但整体影响量较为有限，7月预估有机硅产量环比6月上 ...

在美上市iShares安硕MSCI韩国ETF收跌3.56%，报70.11美元。 在美上市安硕MSCI日本ETF收跌2.39%，报72.815美元。 在美上市iShares安硕MSCI南非ETF收跌1.73%，报53.84美元；南非兰特兑美元维持超过1.55%的跌幅， 暂报17.8504兰特。 在美上市范达越南ETF收涨1.78%，报14.208美元；在美上市Global XMSCI越南ETF收涨1.10%。 ...

Core Insights - Tempus AI (TEM) is advancing precision medicine through a strong pipeline of R&D initiatives, including the introduction of xM, a liquid biopsy assay for advanced solid tumors, and the launch of the Fuses program to enhance AI-enabled diagnostics [1][2][3] Product Development - The company launched olivia, an AI-enabled personal health concierge app, and an FDA-approved NGS-based in vitro diagnostic device, xT CDx, for solid tumor profiling [2] - Tempus AI is developing its first whole-genome sequencing test, xH, aimed at supporting personalized therapy in hematological oncology [3] Competitive Landscape - Peers like Veracyte (VCYT) and Myriad Genetics (MYGN) are also innovating in precision diagnostics, with Veracyte launching the Decipher Prostate test and Myriad introducing the Prequel Prenatal Screen and Foresight Carrier Screening test [4][5] Financial Performance - Over the past year, Tempus AI shares have increased by 83.6%, outperforming the industry growth of 38% and the S&P 500's 12.3% [6] - The company's current forward Price-to-Sales (P/S) ratio is 7.50X, higher than the industry average of 5.88X [8] Earnings Estimates - Earnings estimates for Tempus AI show a mixed outlook for 2025 and 2026, with current estimates remaining stable over the past month [10][11]

Entera Bio's N-Tab Platform and Pipeline - Entera Bio's proprietary N-Tab platform transforms peptides into orally bioavailable tablets, potentially unlocking patient acceptance and driving superior health outcomes[7, 19] - The company's lead asset, EB613, is a differentiated Phase 3 asset poised for blockbuster sales as a first-in-class oral PTH(1-34) anabolic tablet treatment for osteoporosis, a condition affecting over 200 million people worldwide[7, 27] - Entera has a rich pipeline with multiple blockbuster opportunities in high-impact therapeutic areas, including EB612 for hypoparathyroidism, OXM for obesity/metabolic disorders, and GLP-2 for GI inflammatory disorders and short bowel syndrome[7, 8] - The company's cash runway extends into H2 2026, with multiple catalysts expected in the next 12 months[8] EB613 for Osteoporosis - EB613 is positioned as the first oral anabolic treatment to support earlier intervention in osteoporosis, addressing a substantial treatment gap[7, 28] - A Phase 2 study of EB613 in post-menopausal women with low bone mass or osteoporosis demonstrated a faster onset of action and higher increases in BMD at the cortical bone (femoral neck and hip region)[23] - EB613's Phase 2 results showed a distinct dual mechanism of increased bone formation (P1NP) and reduced bone resorption (CTX)[44] - Phase 2 data indicated that EB613 increased BMD at all major skeletal sites, with placebo-adjusted BMD change of EB613 2.5mg from Baseline to Month 6 as Compared with Published Forteo® Data[56, 57] GLP-1/Glucagon and GLP-2 Programs - Entera is developing an oral GLP-1/Glucagon (OXM) dual agonist tablet for metabolic disorders and obesity in partnership with OPKO, with an IND filing expected late 2025/early 2026[8, 104, 116] - Pre-clinical data supports the development of once-daily oral GLP-2 analog tablets for short bowel syndrome (SBS), a rare disease affecting approximately 30,000 patients across the US and EU[8, 106, 108]

Core Insights - Tempus AI is experiencing strong operational momentum with significant revenue and gross profit growth, transitioning from a high-growth startup to a scalable enterprise AI and diagnostics company [1][2] Revenue and Profit Growth - In Q4 2024, Tempus AI reported a 35.8% year-over-year revenue growth and a 49.7% increase in gross profit, primarily driven by its high-margin Data and Services segment [2] - For Q1 2025, revenues grew by 34% and gross profit increased by 45%, with gross margin rising from 42.5% to 44.5% [2][7] - The improvements were attributed to lab efficiencies, increased adoption of AI tools like Tempus One and xM, and a higher mix of data services [2][7] Future Earnings Expectations - The upcoming Q2 2025 earnings release is anticipated to show further margin expansion and sequential gains in adjusted EBITDA, supported by new offerings such as Tempus One in EHR systems and the xM liquid biopsy assay [3] - Any upward revision to guidance or increase in contract value, especially from large enterprise deals, could enhance the momentum observed in early 2025 [3] Competitive Landscape - Tempus AI's peers, such as Guardant Health and Natera, are also making significant advancements in AI-driven diagnostics, with Guardant Health introducing new assays and Natera expanding its market reach [6][8] - Natera reported a 36.5% revenue growth in Q1 2025, with gross margin expansion to 63.1%, indicating a competitive environment in personalized oncology [8] Earnings Estimates - The Zacks Consensus Estimate for Tempus AI's 2025 earnings suggests a 56.3% year-over-year improvement [9] - Current estimates indicate a potential for significant growth in earnings per share, with a year-over-year growth estimate of 63.49% for the current quarter [10] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales (P/S) ratio of 7.52X, which is higher than the industry average of 5.8X, indicating a potentially expensive valuation [11]

Core Viewpoint - The article discusses the emergence of domestic GPU companies in China, particularly in the context of the growing demand for AI technologies and the challenges they face in competing with established players like NVIDIA and AMD [3][6][11]. Group 1: Market Dynamics - The recent surge in IPO applications from domestic GPU companies, including Moore Threads and Muxi, is attributed to a more favorable IPO policy and accelerated review processes on the Sci-Tech Innovation Board [4][5]. - The tightening of U.S. chip export controls has led to a decline in NVIDIA's market share in China, creating a window of opportunity for domestic GPU firms to pursue IPOs [6][12]. - The overall number of IPO applications in the first half of the year reached 177, significantly surpassing the total for the previous year, with June alone accounting for over 80% of the applications [5]. Group 2: Company Profiles - Moore Threads aims to create a "fully functional GPU" targeting both data center and consumer gaming markets, similar to NVIDIA's strategy, and has launched several GPU chips based on its self-developed MUSA architecture [10][11]. - Muxi focuses more on the data center market, particularly AI training and inference, with a product line that includes the Xisi N series, Xiyun C series, and Xicai G series [11]. - Both companies have successfully raised significant funding, with Moore Threads securing over 4.5 billion yuan and Muxi achieving a post-investment valuation of 21.07 billion yuan [11][12]. Group 3: Financial Performance - Moore Threads reported revenues of 46 million yuan in 2022, projected to grow to 438 million yuan by 2024, reflecting a compound annual growth rate (CAGR) of over 200% [13]. - Muxi's revenues are expected to increase from 426,400 yuan in 2022 to 743 million yuan in 2024, with a staggering CAGR of 4,074% [13]. - Despite revenue growth, both companies continue to face significant losses, with Moore Threads reporting losses of 1.84 billion yuan in 2022 and Muxi reporting 777 million yuan in the same year [14]. Group 4: Future Prospects - The article highlights the challenges domestic GPU companies face in building ecosystems to compete with NVIDIA's established software and hardware integration, particularly through CUDA [17]. - Both Moore Threads and Muxi are actively developing their software ecosystems to lower barriers for developers and enhance their competitive positions [17][18]. - The upcoming IPOs are seen as crucial for these companies to secure the necessary capital to continue their growth and development in a highly competitive market [15][16].

文 | 空间秘探，作者 | 李昕羽 近期，某社交平台上一博主分享了其在杭州JW万豪酒店入住时机器人送水的经历，并直言此举对于奢 牌酒店来说是"砸招牌"。这一吐槽迅速引爆评论区，关于高奢酒店该不该用机器人送物的争议持续发酵 ——机器人送物，难道是高奢酒店也开始降本增效了？高奢酒店，到底该不该用机器人送东西？ 机器人送物砸了酒店招牌？ 近期，小红书某用户在平台上分享了其入住杭州JW万豪酒店时机器人送水的经历，意外在评论区掀起 了一场"高奢酒店该不该使用送物机器人"的热烈讨论。 在他看来，区分酒店高档次的标准之一就是不使用机器人送物。"最近这几年住的福朋、万枫、嘉轩这 些基本都是机器人，但是喜来登、凯悦这种全服务的（酒店）极小概率碰到机器人。JW或者君悦这种 完全没到碰过，再往上，丽思、柏悦、半岛、文华这种更不用说了。"文末，他将此次经历总结为酒店 业降本增效的大趋势影响所致。 从笔记的字里行间中可见，博主对于这次杭州JW万豪使用机器人送水的体验感并不是很好，在评论区 回复其他用户时，更鲜明表达其态度：奢牌酒店用机器人绝对是砸招牌，额外花的钱就是用来购买服务 的。 在高奢酒店里，机器人送物到底有没有存在的必要？评论 ...

XmAb® Antibody Therapeutics Antibodies by Design™: May 2019 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trial ...